GSK's ViiV reports positive data for long-acting two-drug HIV therapy

ViiV Healthcare, a company majority owned by GlaxoSmithKline, reported its two-drug combination regimen succeeded in maintaining HIV suppression with injections every eight weeks in a Phase 3 study.